Atrium Therapeutics (RNA) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $7.67, -1.92% vs the prior close of $7.82.
- Volume 190.97K shares, 0.6x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
RNA dips 1.9% to $7.67, a 6-month low. Closed at $7.67, -1.92% vs the prior close of $7.82. Day range $7.67–$8.06, opened at $7.79.
RNA daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — RNA dips 1.9% to $7.67, a 6-month low
- Closed at $7.67, -1.92% vs the prior close of $7.82. Day range $7.67–$8.06, opened at $7.79.
- Volume was 190.97K shares, 0.6x its 50-day average of 296.77K.
- Price is -28.2% vs its 50-day average ($10.69).
- 52-week range $7.54–$16.77; today's close sits at 1% of that range, 54.3% below the 52-week high.
Oct 15, 2026 — RNA rises 1.8% to $7.82
- Closed at $7.82, +1.82% vs the prior close of $7.68. Day range $7.64–$7.87, opened at $7.75.
- Volume was 131.20K shares, 0.4x its 50-day average of 297.59K — lighter than usual.
- Price is -27.4% vs its 50-day average ($10.77).
- 52-week range $7.54–$16.77; today's close sits at 3% of that range, 53.4% below the 52-week high.
Oct 14, 2026 — RNA dips 0.9% to $7.68, a 6-month low, 3 down days in a row
- Closed at $7.68, -0.90% vs the prior close of $7.75. Day range $7.54–$7.94, opened at $7.75.
- Volume was 269.50K shares, 0.9x its 50-day average of 294.94K.
- Price is -29.2% vs its 50-day average ($10.85).
- 52-week range $7.54–$16.77; today's close sits at 2% of that range, 54.2% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — RNA slides 5.6% to $7.75, a 6-month low
- Closed at $7.75, -5.60% vs the prior close of $8.21. Day range $7.75–$8.22, opened at $8.22.
- Volume was 237.20K shares, 0.8x its 50-day average of 292.02K.
- Price is -29.1% vs its 50-day average ($10.93).
- 52-week range $7.63–$16.77; today's close sits at 1% of that range, 53.8% below the 52-week high.
Oct 12, 2026 — RNA dips 2.3% to $8.21
- Closed at $8.21, -2.26% vs the prior close of $8.40. Day range $8.21–$8.48, opened at $8.40.
- Volume was 87.30K shares, 0.3x its 50-day average of 292.60K — lighter than usual.
- Price is -25.4% vs its 50-day average ($11.00).
- 52-week range $7.63–$16.77; today's close sits at 6% of that range, 51.0% below the 52-week high.
Oct 9, 2026 — RNA rises 1.7% to $8.40
- Closed at $8.40, +1.69% vs the prior close of $8.26. Day range $8.13–$8.50, opened at $8.29.
- Volume was 208.30K shares, 0.7x its 50-day average of 290.27K.
- Price is -24.1% vs its 50-day average ($11.06).
- 52-week range $7.63–$16.77; today's close sits at 8% of that range, 49.9% below the 52-week high.
Oct 8, 2026 — RNA jumps 4.2% to $8.26 on 2.3x normal volume
- Closed at $8.26, +4.16% vs the prior close of $7.93. Day range $7.97–$8.33, opened at $8.15.
- Volume was 645.60K shares, 2.3x its 50-day average of 279.75K — unusually heavy trading.
- Price is -25.8% vs its 50-day average ($11.13).
- 52-week range $7.63–$16.77; today's close sits at 7% of that range, 50.7% below the 52-week high.
- SEC filings that day: 8-K.
Oct 7, 2026 — RNA dips 0.8% to $7.93
- Closed at $7.93, -0.75% vs the prior close of $7.99. Day range $7.93–$8.13, opened at $7.95.
- Volume was 91.80K shares, 0.3x its 50-day average of 279.75K — lighter than usual.
- Price is -29.1% vs its 50-day average ($11.18).
- 52-week range $7.63–$16.77; today's close sits at 3% of that range, 52.7% below the 52-week high.
Oct 6, 2026 — RNA ends flat (+0.3%) to $7.99
- Closed at $7.99, +0.25% vs the prior close of $7.97. Day range $7.78–$8.07, opened at $8.00.
- Volume was 411.70K shares, 1.5x its 50-day average of 273.17K.
- Price is -29.0% vs its 50-day average ($11.26).
- 52-week range $7.63–$16.77; today's close sits at 4% of that range, 52.4% below the 52-week high.
Oct 5, 2026 — RNA rises 1.7% to $7.97
- Closed at $7.97, +1.66% vs the prior close of $7.84. Day range $7.63–$8.11, opened at $7.83.
- Volume was 268.30K shares, 1.0x its 50-day average of 270.22K.
- Price is -29.6% vs its 50-day average ($11.33).
- 52-week range $7.63–$16.77; today's close sits at 4% of that range, 52.5% below the 52-week high.
Oct 2, 2026 — RNA slides 3.7% to $7.84, a 6-month low on 2.0x normal volume
- Closed at $7.84, -3.69% vs the prior close of $8.14. Day range $7.68–$8.42, opened at $8.22.
- Volume was 533.80K shares, 2.0x its 50-day average of 261.57K — unusually heavy trading.
- Price is -31.2% vs its 50-day average ($11.40).
- 52-week range $7.68–$16.77; today's close sits at 2% of that range, 53.2% below the 52-week high.
- That makes 4 straight losses.
RNA latest news & SEC filings
Every SEC filing by or about RNA in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 9, 2026 · Form 8-K/A — Current report (amended)
Amended current report
- Item 8.01 — Reported other events the company considers important.
Oct 8, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 3.02 — Sold unregistered shares.
- Item 8.01 — Reported other events the company considers important.
Sep 22, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Younis Husam had withheld for taxes 11,216 shares at $8.95 (≈$100.38K) on Sep 18, 2026; now holds 41,441
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 22, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Hughes Steven George had withheld for taxes 21,459 shares at $8.95 (≈$192.06K) on Sep 18, 2026; now holds 51,638
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 22, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Flanagan W. Michael had withheld for taxes 22,812 shares at $8.95 (≈$204.17K) on Sep 18, 2026; now holds 31,974
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 22, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Boyce Sarah had withheld for taxes 126,418 shares at $8.95 (≈$1.13M) on Sep 18, 2026; now holds 138,668
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 22, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Kenney Stephanie had withheld for taxes 2,375 shares at $8.95 (≈$21.26K) on Sep 18, 2026; now holds 33,085
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 22, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Gallagher Kathleen P. had withheld for taxes 11,632 shares at $8.95 (≈$104.11K) on Sep 18, 2026; now holds 119,729
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $3.00M (prior year $3.85M) (-21.9% vs Jun 30, 2025)
- Net income: -$20.19M (prior year -$12.88M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$1.18 (prior year -$0.75) (loss widened vs Jun 30, 2025)
Aug 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 27, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade RNA
- Last results release: Aug 13, 2026 (8-K Item 2.02). Previous ones: May 14, 2026. Based on that rhythm, the next report is likely around Nov 12, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.26% (largest 9.7%).
- Liquidity: about 303.27K shares (≈$2.33M) trade per day on average.
- 52-week position: $7.67 vs a range of $7.54–$16.77 (1% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Oct 8, 2026; 10-Q Aug 13, 2026; 8-K Aug 13, 2026.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
RNA market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 7.79 | 8.06 | 7.67 | 7.67 | 190.97K |
| Oct 15, 2026 | 7.75 | 7.87 | 7.64 | 7.82 | 131.20K |
| Oct 14, 2026 | 7.75 | 7.94 | 7.54 | 7.68 | 269.50K |
| Oct 13, 2026 | 8.22 | 8.22 | 7.75 | 7.75 | 237.20K |
| Oct 12, 2026 | 8.40 | 8.48 | 8.21 | 8.21 | 87.30K |
| Oct 9, 2026 | 8.29 | 8.50 | 8.13 | 8.40 | 208.30K |
| Oct 8, 2026 | 8.15 | 8.33 | 7.97 | 8.26 | 645.60K |
| Oct 7, 2026 | 7.95 | 8.13 | 7.93 | 7.93 | 91.80K |
| Oct 6, 2026 | 8.00 | 8.07 | 7.78 | 7.99 | 411.70K |
| Oct 5, 2026 | 7.83 | 8.11 | 7.63 | 7.97 | 268.30K |
| Oct 2, 2026 | 8.22 | 8.42 | 7.68 | 7.84 | 533.80K |
| Oct 1, 2026 | 8.30 | 8.44 | 7.96 | 8.14 | 395.70K |
| Sep 30, 2026 | 8.38 | 8.46 | 8.22 | 8.28 | 197.30K |
| Sep 29, 2026 | 8.42 | 8.50 | 8.21 | 8.42 | 158.80K |
| Sep 28, 2026 | 8.21 | 8.52 | 8.05 | 8.42 | 504.90K |
| Sep 25, 2026 | 8.20 | 8.37 | 8.10 | 8.29 | 221.40K |
| Sep 24, 2026 | 8.30 | 8.49 | 8.16 | 8.19 | 355.10K |
| Sep 23, 2026 | 9.22 | 9.31 | 8.29 | 8.33 | 434.00K |
| Sep 22, 2026 | 9.24 | 9.49 | 9.17 | 9.22 | 241.30K |
| Sep 21, 2026 | 8.97 | 9.34 | 8.94 | 9.19 | 481.30K |
About Atrium Therapeutics
Atrium Therapeutics (RNA) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in SAN DIEGO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 2093101.
RNA board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Carsten Boess | Director | Mar 2, 2026 |
| Sarah Boyce | Director | Sep 22, 2026 |
| W. Michael Flanagan | Director | Sep 22, 2026 |
| Kathleen P. Gallagher | See Remarks | Sep 22, 2026 |
| Simona Skerjanec | Director | Mar 2, 2026 |
| Troy Edward Wilson | Director | Mar 2, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Kathleen P. Gallagher | See Remarks | Sep 22, 2026 |
| Rocio Martin Hoyos | Chief Strategy Officer | Sep 22, 2026 |
| Steven George Hughes | Chief Medical Officer | Sep 22, 2026 |
| Stephanie Kenney | See Remarks | Sep 22, 2026 |
| Brendan R. Winslow | Chief Financial Officer | Sep 22, 2026 |
| Husam Younis | Chief Scientific Officer | Sep 22, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
RNA financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| No annual XBRL figures available (foreign filers often report on Form 20-F). | ||||
Latest balance sheet: total assets $280.51M, total liabilities $65.94M, cash $72.33M (as of Jun 30, 2026).
RNA earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 13, 2026 | 8-K Item 2.02 (results) | $12.33 |
| May 14, 2026 | 8-K Item 2.02 (results) | $13.27 |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on RNA
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.